ProfileGDS5678 / 1424014_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 87% 87% 86% 85% 87% 87% 82% 87% 88% 85% 85% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8396488
GSM967853U87-EV human glioblastoma xenograft - Control 26.8868588
GSM967854U87-EV human glioblastoma xenograft - Control 36.72187
GSM967855U87-EV human glioblastoma xenograft - Control 46.9065787
GSM967856U87-EV human glioblastoma xenograft - Control 56.5737186
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2221585
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.482987
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6434287
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9296782
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6932587
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7837688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4058685
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.328685
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7409687